Why the study?
Pulmonary valve replacement is required for RVOT dysfunction, and PPVI offers a less-invasive option, but its effectiveness, safety, and optimal timing needed evaluation.
Does percutaneous pulmonary valve implantation improve mean RVOT gradient and right ventricular remodeling in patients with right ventricular outflow tract dysfunction?
Does percutaneous pulmonary valve implantation improve mean RVOT gradient and right ventricular remodeling in patients with right ventricular outflow tract dysfunction?
Percutaneous pulmonary valve implantation is highly successful and significantly improves hemodynamics and right ventricular remodeling in patients with RVOT dysfunction, with acceptable complication rates.
Answers are grounded in this paper and cite their sources.
PPVI supports less-invasive management of RVOT dysfunction with hemodynamic gains; leaves open optimal timing and durability pending RCTs.
Background: Pulmonary valve replacement is required for patients with right ventricular outflow tract (RVOT) dysfunction. Surgical and percutaneous pulmonary valve replacement are the treatment options. Percutaneous pulmonary valve implantation (PPVI) provides a less-invasive therapy for patients. The aim of this study was to evaluate the effectiveness and safety of PPVI and the optimal time for implantation. Methods: We searched PubMed, EMBASE, Clinical Trial, and Google Scholar databases covering the period until May 2018. The primary effectiveness endpoint was the mean RVOT gradient; the secondary endpoints were the pulmonary regurgitation fraction, left and right ventricular end-diastolic and systolic volume indexes, and left ventricular ejection fraction. The safety endpoints were the complication rates. Results: A total of 20 studies with 1246 participants enrolled were conducted. The RVOT gradient decreased significantly [weighted mean difference (WMD) = −19.63 mmHg; 95% confidence interval (CI): −21.15, −18.11; p < 0.001]. The right ventricular end-diastolic volume index (RVEDVi) was improved (WMD = −17.59 ml/m²; 95% CI: −20.93, −14.24; p < 0.001), but patients with a preoperative RVEDVi >140 ml/m² did not reach the normal size. Pulmonary regurgitation fraction (PRF) was notably decreased (WMD = −26.27%, 95% CI: −34.29, −18.25; p < 0.001). The procedure success rate was 99% (95% CI: 98–99), with a stent fracture rate of 5% (95% CI: 4–6), the pooled infective endocarditis rate was 2% (95% CI: 1–4), and the incidence of reintervention was 5% (95% CI: 4–6). Conclusions: In patients with RVOT dysfunction, PPVI can relieve right ventricular remodeling, improving hemodynamic and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Ran et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: